1. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees
- Author
-
Chow, Eric J, Doody, David R, Wilkes, Jennifer J, Becker, Laura K, Chennupati, Shasank, Morin, Pamela E, Winestone, Lena E, Henk, Henry J, and Lyman, Gary H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Rare Diseases ,Cancer ,Hematology ,Chronic Disease ,Cohort Studies ,Humans ,Imatinib Mesylate ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Protein Kinase Inhibitors ,Chronic myelogenous leukemia ,tyrosine kinase inhibitor ,complications ,epidemiology ,insurance ,Immunology ,Cardiovascular medicine and haematology - Abstract
With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (n = 1200) were identified from the OptumLabs® Data Warehouse (de-identified claims and electronic health records) between 2000 and 2016 and compared with a non-cancer cohort (n = 7635). The 5-year cumulative incidence of all organ system outcomes was significantly greater for the TKI versus non-cancer group. In the first year, compared with imatinib, later generation TKIs were associated with primary infections (hazard ratios [HR] 1.43, 95% CI 1.02-2.00), circulatory events (HR 1.15, 95% CI 1.01-1.31), and skin issues (HR 1.43, 95% CI 1.13-1.80); musculoskeletal and nervous system/sensory issues were less common (HRs 0.83-0.84, p
- Published
- 2021